Cargando…

TO901317 regulating apolipoprotein M expression mediates via the farnesoid X receptor pathway in Caco-2 cells

BACKGROUND: Apolipoprotein M (apoM) may have potential antiatherosclerotic properties. It has been reported that apoM expression could be regulated by many intracellar and extracellar factors. In the present study we further investigated regulation of apoM expression in Caco-2 cells stimulated by a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhu, Chunhua, Di, Dongmei, Zhang, Xiaoying, Luo, Guanghua, Wang, Zongchun, Wei, Jiang, Shi, Yuanping, Berggren-Söderlund, Maria, Nilsson-Ehle, Peter, Xu, Ning
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3219732/ https://www.ncbi.nlm.nih.gov/pubmed/22054074 http://dx.doi.org/10.1186/1476-511X-10-199

Ejemplares similares

Hyperglycemia-induced downregulation of apolipoprotein M expression is not via the hexosamine pathway
por: Jiang, Bo, et al.
Publicado: (2015)

Decreased Activities of Apolipoprotein M Promoter Are Associated with the Susceptibility to Coronary Artery Diseases
por: Zheng, Lu, et al.
Publicado: (2014)

Effects of simvastatin on apolipoprotein M in vivo and in vitro
por: Zhang, Xiaoying, et al.
Publicado: (2011)

Rosiglitazone Enhances Apolipoprotein M (Apom) Expression in Rat's Liver
por: Luo, Guanghua, et al.
Publicado: (2014)

Intralipid Decreases Apolipoprotein M Levels and Insulin Sensitivity in Rats
por: Zheng, Lu, et al.
Publicado: (2014)

Apolipoprotein M
por: Luo, Guanghua, et al.
Publicado: (2004)

Expression and localization of apolipoprotein M in human colorectal tissues
por: Luo, Guanghua, et al.
Publicado: (2010)

Determination of single-nucleotide polymorphism in the proximal promoter region of apolipoprotein M gene in coronary artery diseases
por: Zheng, Lu, et al.
Publicado: (2009)

Decreased Splenic CD4(+) T-Lymphocytes in Apolipoprotein M Gene Deficient Mice
por: Wang, Zhigang, et al.
Publicado: (2015)

Liver X receptors activation, through TO901317 binding, reduces neuroinflammation in Parkinson’s disease
por: Paterniti, Irene, et al.
Publicado: (2017)

Lipid synthesis and secretion in HepG2 cells is not affected by ACTH
por: Skoog, Maria, et al.
Publicado: (2010)

17β-estradiol regulates the expression of apolipoprotein M through estrogen receptor α-specific binding motif in its promoter
por: Wei, Jiang, et al.
Publicado: (2017)

The Liver X Receptor Agonist TO901317 Ameliorates Behavioral Deficits in Two Mouse Models of Autism
por: Cai, Yulong, et al.
Publicado: (2019)

Calcitriol and TO-901317 Interact in Human Prostate Cancer LNCaP Cells
por: Wang, Jing-Huan, et al.
Publicado: (2008)

Insulin Resistance in Apolipoprotein M Knockout Mice is Mediated by the Protein Kinase Akt Signaling Pathway
por: Yao, Shuang, et al.
Publicado: (2020)

Treatment with TO901317, a synthetic liver X receptor agonist, reduces brain damage and attenuates neuroinflammation in experimental intracerebral hemorrhage
por: Wu, Chun-Hu, et al.
Publicado: (2016)

The Farnesoid X Receptor: Good for BAD
por: Keely, Stephen J., et al.
Publicado: (2016)

Molecular tuning of farnesoid X receptor partial agonism
por: Merk, Daniel, et al.
Publicado: (2019)

Stimulation of the farnesoid X receptor promotes M2 macrophage polarization
por: Jaroonwitchawan, Thiranut, et al.
Publicado: (2023)

Activation of the Liver X Receptor by Agonist TO901317 Improves Hepatic Insulin Resistance via Suppressing Reactive Oxygen Species and JNK Pathway
por: Dong, Ying, et al.
Publicado: (2015)

Farnesoid X receptor (FXR): Structures and ligands
por: Jiang, Longying, et al.
Publicado: (2021)

Non-negligible factors in studying the ApoM-S1P axis using EA.hy926 cells
por: Shi, Yuanping, et al.
Publicado: (2020)

Apolipoprotein M promotes the anti-inflammatory effect of high-density lipoprotein by binding to scavenger receptor BI
por: Yao, Shuang, et al.
Publicado: (2020)

Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota
por: Mori, Hideki, et al.
Publicado: (2022)

Diabetic Nephropathy Is Accelerated by Farnesoid X Receptor Deficiency and Inhibited by Farnesoid X Receptor Activation in a Type 1 Diabetes Model
por: Wang, Xiaoxin X., et al.
Publicado: (2010)

Effect of TO901317 on GF to promote the differentiation of human bone marrow mesenchymal stem cells into dopamine neurons on Parkinson’s disease
por: Li, Miaomiao, et al.
Publicado: (2021)

Microbiota-induced obesity requires farnesoid X receptor
por: Parséus, Ava, et al.
Publicado: (2017)

Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases
por: Wu, Jin-nan, et al.
Publicado: (2020)

The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity
por: Rausch, Magdalena, et al.
Publicado: (2022)

Natural Products Targeting Liver X Receptors or Farnesoid X Receptor
por: She, Jianglian, et al.
Publicado: (2022)

Apolipoprotein M promotes cholesterol uptake and efflux from mouse macrophages
por: Yao, Shuang, et al.
Publicado: (2021)

Bacterial metabolites directly modulate farnesoid X receptor activity
por: Zhang, Xianqin, et al.
Publicado: (2015)

Allosteric modulation of the farnesoid X receptor by a small molecule
por: Gabler, Matthias, et al.
Publicado: (2018)

Identification of FDA-approved drugs targeting the Farnesoid X Receptor
por: van de Wiel, Sandra M. W., et al.
Publicado: (2019)

Irisin Is Controlled by Farnesoid X Receptor and Regulates Cholesterol Homeostasis
por: Li, Hong, et al.
Publicado: (2019)

Farnesoid X Receptor Agonists as Therapeutic Target for Cardiometabolic Diseases
por: Li, Chao, et al.
Publicado: (2020)

Farnesoid X Receptor and Liver X Receptor Ligands Initiate Formation of Coated Platelets
por: Unsworth, Amanda J., et al.
Publicado: (2017)

Liver X Receptor Agonist TO901317 Attenuates Paraquat-Induced Acute Lung Injury through Inhibition of NF-κB and JNK/p38 MAPK Signal Pathways
por: Hu, Xiao, et al.
Publicado: (2017)

Farnesoid X receptor knockout protects brain against ischemic injury through reducing neuronal apoptosis in mice
por: Shan, Hui-Min, et al.
Publicado: (2020)

NSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor
por: Schmidt, Jurema, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_09scfismpd4htnhnss878mj058